Pfizer Vaccines, Collegeville, Pennsylvania, USA.
University of Colorado, School of Medicine, Aurora, Colorado, USA.
J Infect Dis. 2022 Mar 15;225(6):1100-1111. doi: 10.1093/infdis/jiaa752.
Although global reviews of infant respiratory syncytial virus (RSV) burden exist, none have summarized data from the United States or evaluated how RSV burden estimates are influenced by variations in study design.
We performed a systematic literature review and meta-analysis of studies describing RSV-associated hospitalization rates among US infants and examined the impact of key study characteristics on these estimates.
We reviewed 3328 articles through 14 August 2020 and identified 25 studies with 31 unique estimates of RSV-associated hospitalization rates. Among US infants <1 year of age, annual rates ranged from 8.4 to 40.8 per 1000 with a pooled rate of 19.4 (95% confidence interval [CI], 17.9-20.9). Study type influenced RSV-associated hospitalization rates (P = .003), with active surveillance studies having pooled rates (11.0; 95% CI, 9.8-12.2) that were half that of studies based on administrative claims (21.4; 19.5-23.3) or modeling approaches (23.2; 20.2-26.2).
Applying our pooled rates to the 2020 US birth cohort suggests that 79 850 (95% CI, 73 680-86 020) RSV-associated infant hospitalizations occur each year. The full range of RSV-associated hospitalization rates identified in our review can better inform future evaluations of RSV prevention strategies. More research is needed to better understand differences in estimated RSV burden across study design.
虽然有全球范围内关于婴儿呼吸道合胞病毒(RSV)负担的综述,但尚无任何综述总结了来自美国的数据,也未评估RSV 负担估计值受研究设计差异的影响情况。
我们对描述美国婴儿因 RSV 住院率的研究进行了系统的文献回顾和荟萃分析,并研究了关键研究特征对这些估计值的影响。
我们于 2020 年 8 月 14 日前查阅了 3328 篇文章,确定了 25 项研究,这些研究共提供了 31 项关于 RSV 相关住院率的独特估计值。在美国 1 岁以下婴儿中,年发生率范围为 8.4 至 40.8/1000,汇总发生率为 19.4(95%置信区间[CI],17.9-20.9)。研究类型影响 RSV 相关住院率(P=.003),主动监测研究的汇总发生率(11.0;95%CI,9.8-12.2)为基于行政索赔(21.4;95%CI,19.5-23.3)或建模方法(23.2;95%CI,20.2-26.2)的一半。
将我们的汇总率应用于 2020 年美国出生队列,表明每年有 79850 例(95%CI,73680-86020)与 RSV 相关的婴儿住院治疗。我们的综述确定了 RSV 相关住院率的全范围,可更好地为未来的 RSV 预防策略评估提供信息。需要进一步研究以更好地了解不同研究设计之间估计的 RSV 负担差异。